The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | The use of TARC as a diagnostic biomarker in Hodgkin lymphoma
Arjan Diepstra, PhD, University of Groningen, Groningen, The Netherlands, shares some insights into why the thymus and activation-regulated chemokine (TARC) protein is an attractive biomarker in Hodgkin lymphoma (HL), highlighting that this protein is an important promoter of Hodgkin Reed-Sternberg cell growth, and is present at high levels in serum making it easily measurable. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
